|
| |
Illumina Launches Multi-Sample Indexing for GoldenGate(R) Assay
New Indexing Technology Offers Optimal Combination of Throughput and Cost for
Low-Complexity Sample Screening
SAN DIEGO- Jul. 2, 2009-- Illumina, Inc. (NASDAQ:ILMN) today launched GoldenGate
Indexing, a high-throughput genotyping solution that utilizes multi-sample
indexing technology. Researchers may now screen up to 16 times as many samples
per reaction as the standard GoldenGate Assay, increasing throughput from 288
samples per day to greater than 2000, while decreasing total reagent
consumption. This high-quality genotyping system includes automation control and
positive sample tracking through an Illumina Laboratory Information Management
System (LIMS), creating a turnkey solution for low-complexity screening at an
affordable cost per sample. The plexity ranges include 96-plex, 192-plex and
384-plex, which are ideal for screening in the livestock and agriculture market
as well as for whole-genome association target validation and quality control
applications.
Livestock geneticists, including Curt Van Tassell of the USDA Agricultural
Research Service, worked with Illumina to develop GoldenGate Indexing and are
now working on a custom panel for screening livestock. Replacing older methods
will allow livestock screening labs to better access genetic information of
value. For example, breeders use SNP data to identify DNA markers for
applications such as identifying parentage and economically important traits,
including disease resistance, marbling, and feed efficiency. With Illumina’s new
GoldenGate Indexing, researchers will have a higher degree of multiplexing
options at a cost they can afford.
“Both livestock and crop researchers have a vested interest in adopting low-plex,
high-sample throughput genotyping as a more efficient method for screening.
GoldenGate Indexing offers genetic laboratories the opportunity to expand their
existing efforts in molecular breeding with a low-cost, fully automated system
for fixed and custom content studies,” said Joel McComb, senior vice president
and general manager of Illumina’s Life Sciences business unit.
The Illumina GoldenGate Assay is a flexible, pre-optimized assay providing
consistent, high-quality genotyping results. GoldenGate Indexing leverages this
proven technology by evolving it into a high-sample throughput solution with
fully integrated automation and sample tracking capabilities.
GoldenGate Indexing represents only one aspect of Illumina’s broad portfolio of
genetic analysis tools for human and agricultural research. Illumina’s array and
sequencing-based technologies support the industry’s broadest range of genetic
analysis applications. For more information, please visit
http://www.illumina.com/goldengateindexing .
About Illumina
Illumina ( www.illumina.com ) is a leading
developer, manufacturer, and marketer of next-generation life-science tools and
integrated systems for the analysis of genetic variation and biological
function. Using our proprietary technologies, we provide a comprehensive line of
products and services that currently serve the sequencing, genotyping, and gene
expression markets, and we expect to enter the market for molecular diagnostics.
Our customers include leading genomic research centers, pharmaceutical
companies, academic institutions, clinical research organizations, and
biotechnology companies. Our tools provide researchers around the world with the
performance, throughput, cost effectiveness, and flexibility necessary to
perform the billions of genetic tests needed to extract valuable medical
information from advances in genomics and proteomics. We believe this
information will enable researchers to correlate genetic variation and
biological function, which will enhance drug discovery and clinical research,
allow diseases to be detected earlier, and permit better choices of drugs for
individual patients.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995: this release may contain forward-looking statements that involve risks and
uncertainties. Among the important factors that could cause actual results to
differ materially from those in any forward-looking statements are Illumina's
ability (i) to develop and commercialize further our BeadArray™, VeraCode®, and
Solexa® technologies and to deploy new sequencing, gene expression, and
genotyping products and applications for our technology platforms, (ii) to
manufacture robust instrumentation and reagents technology, together with other
factors detailed in our filings with the Securities and Exchange Commission
including our recent filings on Forms 10-K and 10-Q or in information disclosed
in public conference calls, the date and time of which are released beforehand.
We disclaim any intent or obligation to update these forward-looking statements
beyond the date of this release.
Source: Illumina, Inc.
Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
858-202-4507
pfromen@illumina.com
or
Media:
Philomena Walsh
Associate Director, Corporate Marketing
858-882-6655
mbornstein@illumina.com
College Hill
Tony Stephenson, Katie Odgaard
+44 (0)20 7866 7864
illumina@collegehill.com
| |
|
